Similar disease burden seen at presentation for osteoarthritis, rheumatoid arthritis

Estradiol independently linked to leucocyte telomere length in older men; SHBG inversely associated

Sometimes our obsession with clinically proven data can get in the way of patient care. We can see that this week in an article about the official indication for the dual SGLT-1/2 inhibitor sotagliflozin. To find out what our patients may end up missing, check out our article #2. Dave …

Monitoring glucose in midlife may help prevent future cardiovascular disease, according to a study published in Diabetes Care.

Sanofi and Lexicon to continue any required studies in effort to move sotagliflozin forward.

Dapagliflozin’s updated package insert confirms efficacy and safety profile for patients with moderate chronic kidney disease.

Paula Trief, PhD received her PhD in Clinical Psychology from Syracuse University. She joined the faculty at SUNY Upstate Medical University in the Department of Psychiatry & Behavioral Sciences in 1993. She is currently a tenured Distinguished Service Professor of Psychiatry & Behavioral Sciences, with joint appointments in the departments of Medicine and Orthopedic Surgery. Academically, she is an active behavioral science researcher, studying behavioral interventions for patients with diabetes. Her current RO1 studies factors that predict medication adherence and healthcare usage in emerging adults with type 2 diabetes.

Clinical utility of T1DM susceptibility genes: One of the goals of genetic studies of complex disease is to identify a profile of susceptibility variants that can be used to predict an individual’s risk of developing a given disease. The long prodrome for T1DM, characterized by progressive loss of beta-cell mass, provides an attractive opportunity for intervention to prevent disease development if “at-risk” individuals can be identified. Currently the best markers of disease risk are a positive family history of T1DM and the presence of autoantibodies to islet cell proteins. Over 90% of T1DM patients have no affected relatives, however, so effective preventive efforts will need to target the general population. Unfortunately screening such huge numbers of individuals for islet autoantibodies is logistically unfeasible, particularly given the need for repeated annual testing for those with a negative result. Genetic markers are therefore needed to stratify risk in the general population,

Pharmacological management recommended for postmenopausal women at high risk for fracture

Simplified med regimens, tailored glycemic targets recommended for those with cognitive impairment